Barclays Maintains Overweight on Legend Biotech, Lowers Price Target to $78

Benzinga Newsdesk www.benzinga.com Negative 81.4%

Neg 81.4% Neu 0% Pos 0%

Barclays analyst Etzer Darout maintains Legend Biotech (NASDAQ:LEGN) with a Overweight and lowers the price target from $80 to $78.